Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD


Abstract

Objective: The aim of this study was to evaluate the cost-effectiveness of the long-acting beta-2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual bronchodilator indacaterol/glycopyrronium (IND/GLY) as a maintenance treatment for COPD patients from the perspective of health care payer in Taiwan.

Patients and methods: We adopted a patient-level simulation model, which included a cohort of COPD patients aged ≥40 years. The intervention used in the study was the treatment using IND/GLY, and comparators were tiotropium or salmeterol/fluticasone combination (SFC). Data related to the efficacy of drugs, incidence of exacerbation, and utility were obtained from clinical studies. Direct costs were estimated from claims data based on the severity of COPD. The cycle length was 6 months (to match forced expiratory volume in 1 second [FEV1] data), and the time horizons included 1, 3, 5, 10 years, and lifetime. Deterministic and probabilistic sensitivity analyses were conducted to test the robustness of the model results. Costs were expressed in US dollars with a discount rate of 3.0%.

Results: Compared to tiotropium and SFC, the incremental cost-effectiveness ratios (ICERs) per quality-adjusted life year (QALY) gained of patients treated with IND/GLY were US$5,987 and US$14,990, respectively. One-way sensitivity analysis revealed that the improvement in FEV1 provided by IND/GLY, the distribution of patients with regard to the severity of COPD, and acute exacerbation rate ratio were the key drivers behind cost-effectiveness. Adopting a willingness to pay of US$60,000 per QALY gained as the threshold, there was a 98.7% probability that IND/GLY was cost-effective compared to tiotropium. Similarly, there was a 99.9% probability that IND/GLY was cost-effective compared to SFC.

Conclusion: As a maintenance treatment for COPD, we consider the dual bronchodilator IND/GLY as a cost-effective strategy when compared to either tiotropium or SFC.

Keywords: COPD; ICS/LABA combination; LABA/LAMA dual bronchodilator; cost-effectiveness; indacaterol/glycopyrronium; maintenance therapy.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Conceptual framework of model: FEV1; IND/GLY. Abbreviations: FEV1, forced expiratory volume in 1 second; GLY, glycopyrronium; IND, indacaterol; LY, life year; QALY, quality-adjusted life year; TDI, Transition Dyspnea Index; SGRQ, St. George’s Respiratory Questionnaire.
Figure 2
Figure 2
Incremental CE scatterplot showing cost per QALY gained through the administration of IND/GLY compared to (A) tiotropium and (B) SFC. Abbreviations: CE, cost-effectiveness; GLY, glycopyrronium; IND, indacaterol; QALY, quality-adjusted life year; SFC, salmeterol/fluticasone combination.
Figure 3
Figure 3
CEAC per QALY gained from IND/GLY. Abbreviations: CEAC, cost-effectiveness acceptability curve; GDP, gross domestic product; GLY, glycopyrronium; IND, indacaterol; LABA, long-acting beta-2 agonist; LAMA, long-acting muscarinic antagonist; QALY, quality-adjusted life year; SFC, salmeterol/fluticasone combination; WTP, willingness-to-pay.
See this image and copyright information in PMC

Similar articles